• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

黑色素瘤患者放疗中联合与间断 BRAF 抑制剂治疗的临床结局。

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.

机构信息

Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany.

Department of Dermatology, University Hospital Dresden, Dresden, Germany.

出版信息

Br J Cancer. 2018 Mar 20;118(6):785-792. doi: 10.1038/bjc.2017.489. Epub 2018 Feb 13.

DOI:10.1038/bjc.2017.489
PMID:29438368
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5886123/
Abstract

This corrects the article DOI: 10.1038/bjc.2017.85.

摘要

该文已更正 DOI：10.1038/bjc.2017.85。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e1c/5886123/f82aceaa8b90/bjc2017489f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e1c/5886123/75c3cae2e7f6/bjc2017489f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e1c/5886123/f82aceaa8b90/bjc2017489f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e1c/5886123/75c3cae2e7f6/bjc2017489f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e1c/5886123/f82aceaa8b90/bjc2017489f2.jpg

相似文献

1
Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.黑色素瘤患者放疗中联合与间断 BRAF 抑制剂治疗的临床结局。
Br J Cancer. 2018 Mar 20;118(6):785-792. doi: 10.1038/bjc.2017.489. Epub 2018 Feb 13.
2
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.转移性黑色素瘤患者接受依匹单抗和 BRAF 抑制剂序贯治疗：依匹单抗扩展使用项目意大利队列研究数据。
Cancer Invest. 2014 May;32(4):144-9. doi: 10.3109/07357907.2014.885984. Epub 2014 Jan 31.
3
Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.BRAF 突变型黑色素瘤脑转移患者中 BRAF 抑制和 MEK 抑制的临床及影像学反应
Melanoma Res. 2018 Apr;28(2):126-133. doi: 10.1097/CMR.0000000000000429.
4
Improved overall survival in melanoma with combined dabrafenib and trametinib.达拉非尼和曲美替尼联合治疗可改善黑色素瘤患者的总生存期。
N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.
5
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.BRAF 抑制剂单独及联合 MEK 抑制剂治疗转移性黑色素瘤的皮肤毒性作用。
JAMA Dermatol. 2015 Oct;151(10):1103-9. doi: 10.1001/jamadermatol.2015.1745.
6
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.达拉非尼联合曲美替尼与维莫非尼单药治疗不可切除或转移性皮肤 BRAF Val600 突变阳性黑色素瘤患者的健康相关生活质量比较（COMBI-v）：一项开放标签、随机、3 期临床试验结果。
Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X.
7
Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.一名局部晚期BRAF V600E突变黑色素瘤患者成功接受（新）辅助BRAF靶向治疗。
Melanoma Res. 2015 Apr;25(2):180-3. doi: 10.1097/CMR.0000000000000145.
8
Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare.一名有症状性黑色素瘤发作的患者成功再次接受抗BRAF和抗MEK治疗。
Eur J Cancer. 2017 Sep;82:25-26. doi: 10.1016/j.ejca.2017.05.039. Epub 2017 Jun 21.
9
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients.BRAF 抑制剂治疗的放射增敏作用-黑色素瘤患者的毒性机制和频率。
Ann Oncol. 2015 Jun;26(6):1238-1244. doi: 10.1093/annonc/mdv139. Epub 2015 Mar 11.
10
BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports.BRAF外显子11突变型黑色素瘤与对BRAF/MEK抑制的敏感性：两例病例报告。
Eur J Cancer. 2019 Nov;121:109-112. doi: 10.1016/j.ejca.2019.08.029. Epub 2019 Sep 27.

引用本文的文献

1
Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art.创新全身治疗联合放疗用于骨转移的疗效：欧洲骨转移研究组（GEMO）的最新进展
Cancer Metastasis Rev. 2025 Jan 29;44(1):28. doi: 10.1007/s10555-024-10236-0.
2
The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma.联合靶向PARP-1和c-Met对野生型BRAF黑色素瘤放疗疗效的益处。
Front Med (Lausanne). 2023 May 4;10:1149918. doi: 10.3389/fmed.2023.1149918. eCollection 2023.
3
Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials.

本文引用的文献

1
Clinical Pharmacokinetics of Vemurafenib.维莫非尼的临床药代动力学。
Clin Pharmacokinet. 2017 Sep;56(9):1033-1043. doi: 10.1007/s40262-017-0523-7.
2
Current treatment options of brain metastases and outcomes in patients with malignant melanoma.恶性黑色素瘤患者脑转移的当前治疗选择及治疗结果。
Rep Pract Oncol Radiother. 2016 May-Jun;21(3):271-7. doi: 10.1016/j.rpor.2015.12.001. Epub 2015 Dec 29.
3
Cell cycle arrest caused by MEK/ERK signaling is a mechanism for suppressing growth of antigen-hyperstimulated effector T cells.
靶向人类癌症中的RAS-RAF-MEK-ERK信号通路：临床试验现状
Genes Dis. 2022 May 20;10(1):76-88. doi: 10.1016/j.gendis.2022.05.006. eCollection 2023 Jan.
4
Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive Mutant Advanced Melanoma.达拉非尼-曲美替尼与放疗用于寡进展性突变晚期黑色素瘤
Biomedicines. 2023 Jan 29;11(2):394. doi: 10.3390/biomedicines11020394.
5
Tumor-specific radiosensitizing effect of the ATM inhibitor AZD0156 in melanoma cells with low toxicity to healthy fibroblasts.ATM 抑制剂 AZD0156 对低毒性健康成纤维细胞的黑色素瘤细胞具有肿瘤特异性增敏作用。
Strahlenther Onkol. 2023 Dec;199(12):1128-1139. doi: 10.1007/s00066-022-02009-x. Epub 2022 Oct 13.
6
Kinase inhibitors increase individual radiation sensitivity in normal cells of cancer patients.激酶抑制剂增加癌症患者正常细胞的个体辐射敏感性。
Strahlenther Onkol. 2022 Sep;198(9):838-848. doi: 10.1007/s00066-022-01945-y. Epub 2022 Apr 26.
7
Translation of Precision Medicine Research Into Biomarker-Informed Care in Radiation Oncology.精准医学研究向放射肿瘤学中基于生物标志物的护理的转化。
Semin Radiat Oncol. 2022 Jan;32(1):42-53. doi: 10.1016/j.semradonc.2021.09.001.
8
Radiotherapy in the Treatment of Subcutaneous Melanoma.放射疗法在皮下黑色素瘤治疗中的应用
Cancers (Basel). 2021 Nov 22;13(22):5859. doi: 10.3390/cancers13225859.
9
Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation.帕博西尼可诱导黑色素瘤和乳腺癌细胞衰老，并与放疗联合导致相加性生长停滞。
Front Oncol. 2021 Oct 13;11:740002. doi: 10.3389/fonc.2021.740002. eCollection 2021.
10
Continued versus Interrupted Targeted Therapy during Metastasis-Directed Stereotactic Radiotherapy: A Retrospective Multi-Center Safety and Efficacy Analysis.转移灶定向立体定向放射治疗期间持续与中断靶向治疗：一项回顾性多中心安全性和疗效分析
Cancers (Basel). 2021 Sep 24;13(19):4780. doi: 10.3390/cancers13194780.
由MEK/ERK信号传导引起的细胞周期停滞是抑制抗原过度刺激的效应T细胞生长的一种机制。
Int Immunol. 2016 Nov;28(11):547-557. doi: 10.1093/intimm/dxw037. Epub 2016 Aug 19.
4
Hypofractionated stereotactic radiotherapy for brain metastases from lung cancer : Evaluation of indications and predictors of local control.肺癌脑转移瘤的大分割立体定向放射治疗：局部控制的适应证及预测因素评估
Strahlenther Onkol. 2016 Jun;192(6):386-93. doi: 10.1007/s00066-016-0963-2. Epub 2016 May 11.
5
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).避免BRAF抑制剂与放射治疗联合使用时的严重毒性：东部肿瘤协作组（ECOG）的共识指南
Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):632-46. doi: 10.1016/j.ijrobp.2016.01.038.
6
A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab.对接受伊匹单抗治疗的转移性黑色素瘤患者放疗后远隔效应的系统评价。
Oncoimmunology. 2015 May 28;4(11):e1046028. doi: 10.1080/2162402X.2015.1046028. eCollection 2015 Nov.
7
BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma.晚期BRAF V600突变型黑色素瘤患者的BRAF抑制剂再激发治疗
Melanoma Res. 2015 Dec;25(6):559-63. doi: 10.1097/CMR.0000000000000196.
8
A core of kinase-regulated interactomes defines the neoplastic MDSC lineage.激酶调节的相互作用组核心定义了肿瘤性髓系来源抑制细胞谱系。
Oncotarget. 2015 Sep 29;6(29):27160-75. doi: 10.18632/oncotarget.4746.
9
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence.放疗后的肿瘤微环境：耐药及复发机制
Nat Rev Cancer. 2015 Jul;15(7):409-25. doi: 10.1038/nrc3958.
10
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients.BRAF 抑制剂治疗的放射增敏作用-黑色素瘤患者的毒性机制和频率。
Ann Oncol. 2015 Jun;26(6):1238-1244. doi: 10.1093/annonc/mdv139. Epub 2015 Mar 11.